Education
About Us
Working with TipRanks
Follow Us
Inhibrx Biosciences Inc (INBX)
NASDAQ:INBX
INBX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.81 - $26.00
Previous CloseN/A
Volume23.61K
Average Volume (3M)109.72K
Market Cap
$375.39M
Enterprise Value$140.95M
Total Cash (Recent Filing)$186.57M
Total Debt (Recent Filing)$7.51M
Price to Earnings (P/E)0.2
Beta0.52
Next Earnings
Nov 13, 2025EPS Estimate
-1.72Last Dividend Ex-Date
May 30, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding14,485,421
10 Day Avg. Volume119,188
30 Day Avg. Volume109,718
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.38
Enterprise Value/Revenue100.68
Enterprise Value/Gross Profit-101.62
Enterprise Value/Ebitda-0.89
Forecast
1Y Price Target
$24.50Price Target Upside-10.58% Downside
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe INBRX-106 Phase 1 trial in HNSCC patients showed a 50% overall response rate, including complete and partial responses.
Financial StabilityInhibrx is well capitalized with $196.3 million in cash, allowing continued development of its key treatments.
Treatment EffectivenessThe combination of ozekibart and FOLFIRI shows a promising 40% overall response rate (ORR) in patients with 2L+ CRC, leading to a 7.85-month median progression-free survival (mPFS).
Bears Say
Adverse Effects31% of patients experienced an increase in alanine aminotransferase, indicating potential safety issues.
Safety ConcernsA patient passed away due to neutropenic sepsis, raising concerns about the safety profile of the treatment.
Treatment LimitationsThe safety profile of the combination therapy may limit its use, especially given the grade 5 event possibly linked to FOLFIRI.
Inhibrx Biosciences Inc News
INBX FAQ
What was Inhibrx Biosciences Inc’s price range in the past 12 months?
Inhibrx Biosciences Inc lowest stock price was $10.80 and its highest was $26.00 in the past 12 months.
What is Inhibrx Biosciences Inc’s market cap?
Inhibrx Biosciences Inc’s market cap is $375.39M.
When is Inhibrx Biosciences Inc’s upcoming earnings report date?
Inhibrx Biosciences Inc’s upcoming earnings report date is Nov 13, 2025 which is in 77 days.
How were Inhibrx Biosciences Inc’s earnings last quarter?
Inhibrx Biosciences Inc released its earnings results on Aug 13, 2025. The company reported -$1.85 earnings per share for the quarter, beating the consensus estimate of -$2.76 by $0.91.
Is Inhibrx Biosciences Inc overvalued?
According to Wall Street analysts Inhibrx Biosciences Inc’s price is currently Overvalued.
Does Inhibrx Biosciences Inc pay dividends?
Inhibrx Biosciences Inc pays a Notavailable dividend of $0.85 which represents an annual dividend yield of N/A. See more information on Inhibrx Biosciences Inc dividends here
What is Inhibrx Biosciences Inc’s EPS estimate?
Inhibrx Biosciences Inc’s EPS estimate is -1.72.
How many shares outstanding does Inhibrx Biosciences Inc have?
Inhibrx Biosciences Inc has 14,485,421 shares outstanding.
What happened to Inhibrx Biosciences Inc’s price movement after its last earnings report?
Inhibrx Biosciences Inc reported an EPS of -$1.85 in its last earnings report, beating expectations of -$2.76. Following the earnings report the stock price went up 7.527%.
Which hedge fund is a major shareholder of Inhibrx Biosciences Inc?
Currently, no hedge funds are holding shares in INBX
Inhibrx Biosciences Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$24.50 (-10.58% Downside)
$24.50 (-10.58% Downside)
Hedge Fund Trend
Increased
By 218.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.03%
12-Months-Change
Fundamentals
Return on Equity
-113.71%
Trailing 12-Months
Asset Growth
-17.92%
Trailing 12-Months
Company Description
Inhibrx Biosciences Inc
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
INBX Stock 12 Month Forecast
Average Price Target
$24.50
▼(-10.58% Downside)
Technical Analysis
Prothena
―
CytomX Therapeutics
―
Humacyte
―
Monte Rosa Therapeutics
―
Candel Therapeutics
―
Ownership Overview
15.46% Insiders
6.59% Mutual Funds
45.85% Other Institutional Investors
24.58% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---